Immutep Ltd Adr Stock Today
| IMMP Stock | USD 1.85 0.03 1.65% |
PerformanceVery Weak
| Odds Of DistressLow
|
Immutep is selling at 1.85 as of the 19th of March 2025; that is 1.65% increase since the beginning of the trading day. The stock's last reported lowest price was 1.82. Immutep has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of April 2012 | Category Healthcare | Classification Health Care |
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia. Immutep operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 145.56 M outstanding shares of which 5.09 M shares are currently shorted by private and institutional investors with about 69.58 trading days to cover. More on Immutep Ltd ADR
Moving together with Immutep Stock
Moving against Immutep Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Immutep Stock Highlights
| CEO, Executive Director | Marc Voigt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmutep can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immutep's financial leverage. It provides some insight into what part of Immutep's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immutep Ltd ADR (IMMP) is traded on NASDAQ Exchange in USA. It is located in Australia Square, Sydney, NSW, Australia, 2000 and employs 9 people. Immutep is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 266.66 M. Immutep Ltd ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 145.56 M outstanding shares of which 5.09 M shares are currently shorted by private and institutional investors with about 69.58 trading days to cover.
Immutep Ltd ADR currently holds about 80 M in cash with (34.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92.
Check Immutep Probability Of Bankruptcy
Ownership AllocationImmutep Ltd ADR has a total of 145.56 Million outstanding shares. Roughly 97.94 (percent) of Immutep outstanding shares are held by general public with 0.01 % owned by insiders and only 2.05 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immutep Ownership Details
Immutep Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 29.6 K | |
| Rhumbline Advisers | 2024-12-31 | 28.7 K | |
| Ubs Group Ag | 2024-12-31 | 23 K | |
| Geode Capital Management, Llc | 2024-12-31 | 18.7 K | |
| Old Mission Capital Llc | 2024-12-31 | 16.8 K | |
| Millennium Management Llc | 2024-12-31 | 16.4 K | |
| Simplex Trading, Llc | 2024-12-31 | 10.3 K | |
| Tower Research Capital Llc | 2024-12-31 | 5.6 K | |
| Royal Bank Of Canada | 2024-12-31 | 4.9 K | |
| Blackrock Inc | 2024-12-31 | 740.4 K | |
| Meridian Wealth Management, Llc | 2024-12-31 | 394.1 K |
Immutep Historical Income Statement
Immutep Stock Against Markets
Immutep Corporate Management
| Indira Naidu | Joint Secretary | Profile | |
| Christian Mueller | Director Affairs | Profile | |
| Shengfei Fang | F Sec | Profile | |
| MD MSc | Chief Officer | Profile | |
| MSc BBA | Senior Strategy | Profile |
Additional Tools for Immutep Stock Analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.